Takeda Pharmaceutical revenue and financials
¥5,766.00Change from previous close: +0.82%Absolute change: +¥47.00
In the fiscal year ended March 2026, Takeda Pharmaceutical reported revenue of ¥4.51T (−1.66% year over year). The net loss was ¥152.39B.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −1.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3.4%
- FY to Mar 2025: 2.4%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total revenue | 1,219,900 | 1,094,541 | 1,191,698 | 1,112,796 | 1,106,685 |
| Cost of revenue | 406,676 | 405,704 | 401,148 | 380,061 | 384,675 |
| Gross profit | 813,224 | 688,837 | 790,550 | 732,735 | 722,010 |
| Selling, general and administrative | 286,513 | 291,996 | 282,783 | 253,551 | 255,885 |
| Research and development | 167,395 | 195,320 | 175,231 | 161,482 | 143,891 |
| Operating income | 201,417 | 42,068 | 168,822 | 68,996 | 184,565 |
| EBIT | 226,563 | -620,823 | 257,491 | 111,312 | 257,788 |
| EBITDA | 337,491 | -456,953 | 448,130 | 316,467 | 389,426 |
| Interest expense | 63,845 | -165,800 | 123,627 | 83,138 | 107,158 |
| Pre-tax income | 162,718 | -455,023 | 133,864 | 28,174 | 150,630 |
| Income tax | 49,462 | -86,615 | 30,131 | 39,903 | 26,351 |
| Net income | 113,197 | -368,471 | 103,640 | -11,802 | 124,243 |
| Net income to common shareholders | 113,197 | -368,471 | 103,640 | -11,802 | 124,243 |
| Basic EPS | 71.65 | — | — | — | 79.40 |
| Diluted EPS | 70.54 | — | — | — | 78.23 |
| Average shares (basic) | 1,580 | — | — | — | 1,565 |
| Average shares (diluted) | 1,605 | — | — | — | 1,588 |